- Home
- URGN vs COLL Comparison
URGN vs COLL Comparison
Compare URGN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- COLL
- Stock Information
- Founded
- URGN 2004
- COLL 2002
- Country
- URGN United States
- COLL United States
- Employees
- URGN N/A
- COLL N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- URGN Health Care
- COLL Health Care
- Exchange
- URGN Nasdaq
- COLL Nasdaq
- Market Cap
- URGN 904.0M
- COLL 958.8M
- IPO Year
- URGN 2017
- COLL 2015
- Fundamental
- Price
- URGN $18.79
- COLL $37.32
- Analyst Decision
- URGN Strong Buy
- COLL Strong Buy
- Analyst Count
- URGN 8
- COLL 4
- Target Price
- URGN $28.50
- COLL $44.25
- AVG Volume (30 Days)
- URGN 1.1M
- COLL 433.7K
- Earning Date
- URGN 11-05-2025
- COLL 11-06-2025
- Dividend Yield
- URGN N/A
- COLL N/A
- EPS Growth
- URGN N/A
- COLL N/A
- EPS
- URGN N/A
- COLL 1.06
- Revenue
- URGN $94,238,000.00
- COLL $707,007,000.00
- Revenue This Year
- URGN $39.63
- COLL $22.23
- Revenue Next Year
- URGN $111.49
- COLL $2.78
- P/E Ratio
- URGN N/A
- COLL $35.25
- Revenue Growth
- URGN 10.85
- COLL 22.61
- 52 Week Low
- URGN $3.42
- COLL $23.23
- 52 Week High
- URGN $21.71
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- URGN 48.50
- COLL 50.80
- Support Level
- URGN $18.45
- COLL $37.10
- Resistance Level
- URGN $21.71
- COLL $39.12
- Average True Range (ATR)
- URGN 1.18
- COLL 1.09
- MACD
- URGN -0.18
- COLL -0.38
- Stochastic Oscillator
- URGN 17.51
- COLL 8.55
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.